Literature DB >> 24664585

Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis.

Yinlong Yang1, Jinxian Qian, Yizuo Chen, Yifei Pan.   

Abstract

Circulating microRNAs (miRNAs) exhibit altered expression in patients with cancer and could be considered as potential prognostic biomarker of cancer. Here, we performed a meta-analysis to summarize all the results from available studies, aiming to analyze the prognostic role of circulating microRNA-21 (miR-21) in human cancers. Eligible studies were identified from PubMed and EMBASE through multiple search strategies. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of circulating miR-21 in patients with a variety of carcinomas. Pooled HRs and 95 % confidence intervals (CIs) were calculated. Eleven studies with a total of 1,224 patients with various carcinomas were included this meta-analysis. For OS, higher circulating miR-21 expression could significantly predict worse outcome with the pooled HR of 2.11 (95 % CI 1.36-3.26, P = 0.0009). The subgroup analysis suggested that the elevated circulating miR-21 expression was correlated with worse OS in Asian population with the pooled HR of 2.36 (95 % CI 1.61-3.48, P < 0.0001) and digestive system cancers with the pooled HR of 2.19 (95 % CI 1.01-4.75, P = 0.05). The present meta-analysis suggests that circulating miR-21 expression is associated with poor survival in patients with cancer and could be a prognostic biomarker for those patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664585     DOI: 10.1007/s13277-014-1846-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  47 in total

Review 1.  MicroRNAs in diagnosis and prognosis in cancer: what does the future hold?

Authors:  Patrick Nana-Sinkam; Carlo M Croce
Journal:  Pharmacogenomics       Date:  2010-05       Impact factor: 2.533

2.  MicroRNA expression profiles in serous ovarian carcinoma.

Authors:  Eun Ji Nam; Heejei Yoon; Sang Wun Kim; Hoguen Kim; Young Tae Kim; Jae Hoon Kim; Jae Wook Kim; Sunghoon Kim
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

3.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

Review 4.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

5.  Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer.

Authors:  Yun-Zhao Xu; Qing-Hua Xi; Wen-Liang Ge; Xiao-Qian Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2013

6.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.

Authors:  Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson
Journal:  Nature       Date:  2005-01-30       Impact factor: 49.962

7.  Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.

Authors:  Xing-xiang Pu; Guo-liang Huang; Hong-qiang Guo; Cheng-cheng Guo; Haoran Li; Shen Ye; Suxia Ling; Li Jiang; Ying Tian; Tong-yu Lin
Journal:  J Gastroenterol Hepatol       Date:  2010-10       Impact factor: 4.029

8.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

9.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

10.  Prognostic implications of serum microRNA-21 in colorectal cancer.

Authors:  Pablo Menéndez; David Padilla; Pedro Villarejo; Teodoro Palomino; Patricia Nieto; José M Menéndez; José A Rodríguez-Montes
Journal:  J Surg Oncol       Date:  2013-08-23       Impact factor: 3.454

View more
  6 in total

1.  Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis.

Authors:  Xiao-Yan He; Yu-Dong Liao; Xiao-Qing Guo; Robin Wang; Zhen-Yu Xiao; Yan-Gang Wang
Journal:  Mol Neurobiol       Date:  2015-03-20       Impact factor: 5.590

Review 2.  Challenges of deciphering gastric cancer heterogeneity.

Authors:  Petra Hudler
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

3.  Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis.

Authors:  Jianchun Wu; Zhihong Fang; Jing Xu; Weikang Zhu; Yan Li; Yongchun Yu
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

4.  Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers.

Authors:  Hankui Chen; Helu Liu; Hanqing Zou; Rui Chen; Yuhong Dou; Shile Sheng; Shengming Dai; Junmei Ai; Joshua Melson; Rick A Kittles; Mehdi Pirooznia; Michael J Liptay; Jeffrey A Borgia; Youping Deng
Journal:  J Cancer       Date:  2016-02-05       Impact factor: 4.207

Review 5.  The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis.

Authors:  Qiliang Peng; Xueli Zhang; Ming Min; Li Zou; Peipei Shen; Yaqun Zhu
Journal:  Oncotarget       Date:  2017-07-04

Review 6.  Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.

Authors:  Kai Qu; Ting Lin; Qing Pang; Tian Liu; Zhixin Wang; Minghui Tai; Fandi Meng; Jingyao Zhang; Yong Wan; Ping Mao; Xiaoqun Dong; Chang Liu; Wenquan Niu; Shunbin Dong
Journal:  Oncotarget       Date:  2016-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.